title: Incidence of streptococcal carriers in private pediatric practice.
abstract: OBJECTIVE
  To determine the incidence of group A beta-hemolytic streptococcus (GABHS) carriers in children who are well, in children seen with presumed and documented viral illnesses with sore throat, and in children after treatment of acute GABHS tonsillopharyngitis with 10 days of oral penicillin V potassium, oral cephalosporins, or macrolides.
  
  
  METHODS
  Prospective collection of clinical and microbiologic data from October 1996 to June 1997 in a private pediatric practice were obtained from children who were asymptomatic and well, from children with both presumed (and documented) viral sore throats, and from children who had completed a full antibiotic treatment course for acute GABHS throat infections.
  
  
  RESULTS
  The incidence of GABHS carriers was 2.5% among well children (n = 227), 4.4% among children with upper respiratory tract infections including sore throat of presumed viral etiology (n= 296), and 6.9% among children with upper respiratory tract infections including sore throat from whom viruses were isolated (n = 87). Following 10 days' treatment of acute GABHS tonsillopharyngitis, 81 (11.3%) of 718 children treated with penicillin, 22 (4.3%) of 508 children treated with an oral cephalosporin, and 10 (7.1%) of 140 children treated with a macrolide were GABHS carriers (P<.001).
  
  
  CONCLUSIONS
  A small percentage of children seen in private pediatric practices who are well or who have apparent viral upper respiratory tract infections with sore throat are GABHS carriers. Penicillin treatment of acute GABHS tonsillopharyngitis results in a higher GABHS carriage rate than occurs following treatment with cephalosporins and macrolides.
authors.affiliation: Department of Microbiology and Immunology, University of Rochester Medical Center, NY 14642, USA. mepo@uhura.cc.rochester.edu
authors.forename: M E
authors.initials: ME
authors.lastname: Pichichero
authors.forename: S M
authors.initials: SM
authors.lastname: Marsocci
authors.forename: M L
authors.initials: ML
authors.lastname: Murphy
authors.forename: W
authors.initials: W
authors.lastname: Hoeger
authors.forename: J L
authors.initials: JL
authors.lastname: Green
authors.forename: A
authors.initials: A
authors.lastname: Sorrento
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002353:Carrier State / Q000188:drug therapy / Q000453:epidemiology*; D002511:Cephalosporins / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D015994:Incidence; D018942:Macrolides; D008297:Male; D009518:New York / Q000453:epidemiology; D010372:Pediatrics; D010404:Penicillin V / Q000627:therapeutic use*; D010406:Penicillins / Q000627:therapeutic use*; D010612:Pharyngitis / Q000188:drug therapy / Q000382:microbiology* / Q000821:virology; D011331:Private Practice / Q000706:statistics & numerical data; D011446:Prospective Studies; D013290:Streptococcal Infections / Q000188:drug therapy / Q000453:epidemiology*; D013297:Streptococcus pyogenes / Q000187:drug effects / Q000302:isolation & purification*
chemical_list: D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D018942:Macrolides; D010406:Penicillins; D010404:Penicillin V